Moving towards personalized treatments of immune-related adverse events

Nature Reviews Clinical Oncology, Published online: 03 April 2020; doi:10.1038/s41571-020-0352-8The treatment of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors has mostly been based on adapting therapeutic approaches used in the management of primary autoimmune diseases. The authors of this Review provide an overview of the different cellular and soluble immune factors involved in the pathogenesis of irAEs in order to help clinicians deliver personalized immunopathologically guided treatment to manage these adverse events.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research